Replies to post #241956 on Avid Bioservices Inc (CDMO)

[nuke661]

Thanks CJ for the great info.

Can't wait for those new Phase 1 anti PD-1+Bavi+Chemos trial(s) listed as conceptual in the pipeline chart to get started. I feel very encouraged that if we are just hearing about this paper with Duke collaborators with such great pre-clinical results then the BP and Peregrine collaboration planning for this combo must be well along. I won't be surprised if AZN collaboration is expanded one more time in short order to include the chemo regimen.

Thanks CJ for your tireless efforts for keeping this board organized and well informed.

Also, thanks Hutschi and Biopharm for your great efforts too.

[sunstar]

Here’s a breast cancer collaboration with Duke University. Lead author, Dr. Herbert Kim Lyerly: http://surgery.duke.edu/faculty/details/0117267 (Professor of Surgery, Assistant Professor in Immunology, Associate Professor of Pathology, Duke Univ.

Thank you cjgaddy.

Peregrine has referred to dozens of collaborations. This is just one more coming to light.

Journal for Immuno Therapy of Cancer

http://www.immunotherapyofcancer.org/content/pdf/2051-1426-3-S2-P357.pdf

“CONCLUSION: These results support combination blockade of PS & PD-1/PD-L1 with paclitaxel to treat breast cancer.”

More combination immunotherapy trials are in the PPHM docket.

IMO

sunstar

[biopharm]

Thanks for the post CJ!

SITC'15, Poster=B357(Bavi+PD-L1/Breast), Senior-Author: Duke's Dr. Herbert K. Lyerly. The Lead(publishing) author is Peregrine's Dr. Michael Gray, but interesting that Dr. Lyerly is listed as the last author (typically the Senior Author), along with 2 other Duke researchers listed as co-authors. Clearly Duke is working with Peregrine on pre-clinical bavituximab cancer I-O combination studies.
...As Johnny Carson would say, “I did not know that.”

2 other Duke scientists are listed as co-authors:
* Dr. Takuya Osada (MD/PhD – Duke Cancer Inst. - Hematology, Oncology, Clinical Immunology www.researchgate.net/profile/Takuya_Osada2 )
* Dr. Zachary Hartman (PhD) – Duke MC, Section of Applied Therapeutics http://surgery.duke.edu/faculty/details/0281172 ”My group is also involved in strategies to modulate the immune response to tumors, which involves the use of novel immunotherapeutic strategies & dev. of vaccines to specific oncogenic targets.” ..
..
..

Here we have another dual company profile, for Peregrine scientist Michael Gray that is also still working for Quanticel (Celgene subsidiary)

-----------------------------

Tumors are comprised of different types of cancer cells at different stages of development.

Quanticel's proprietary technology enables isolation, characterization, and targeting of the individual tumor cells that are responsible for cancer recurrence.
..
..
Quanticel Pharmaceuticals has become a wholly owned subsidiary of Celgene Corporation. Visitors to this website will still be able to access relevant Quanticel content.

http://www.quanticel.com/

Michael Gray

scientist at Peregrine Pharmaceuticals
Orange County, California Area
Pharmaceuticals

Current
Peregrine Pharmaceuticals, Quanticel Pharmaceuticals

Previous
OSI

Education
MD Anderson Cancer Center

128
connections


Experience

scientist
Peregrine Pharmaceuticals
December 2014 – Present (1 year)

Scientist
Quanticel Pharmaceuticals
April 2013 – Present (2 years 8 months)

Senior scientist
OSI
2007 – 2010 (3 years)
..
..
..
https://www.linkedin.com/in/michael-gray-18447328